Australian Pharmaxis Reports Positive Results From Phase III Bronchitol Cystic Fibrosis Study
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-based Pharmaxis announced Dec. 2 positive headline results from its second Phase III trial of Bronchitol (mannitol) in people with cystic fibrosis
You may also be interested in...
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months
What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)
PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months
Australia's Pharmaxis Breathing Easier Following U.S. FDA Advisory Committee Recommendation For Bronchial Test Aridol
PERTH, Australia - Sydney-based Pharmaxis is breathing easier following a positive recommendation from U.S. FDA's Pulmonary-Allergy Drugs Advisory Committee Nov. 20 for approval of its bronchial test Aridol